Intra-striatal co-transplantation of autologous treg and mda cells in parkinson's disease cell therapy

The method of any one of the preceding claims, wherein the TREG cells and the mDA cells are autologous TREG cells and autologous mDA cells.

A method of treating a subject having Parkinson's Disease (PD), the method comprising administering to the subject a population of midbrain dopamine (mDA) cells and an antibody (Ab) (optionally, an antibody that binds a pro-inflammatory cytokine or a damage-associated molecular patterns (DAMPs) molecule;

• optionally an anti-TNF-α Ab (optionally Infliximab), an anti-IL-1β Ab (optionally Canakinumab), an anti-IFN-γ Ab (optionally Emapalumab), an anti-HMGB1 Ab, or an anti-IL-1α Ab).

A method of decreasing an immune response in a subject (e.g., an immune response triggered by needle trauma, an immune response at the site of administration) during cell transplantation, the method comprising administering to the subject an effective amount of a population of TREG cells with a second population of cells.

A method of decreasing an immune response in a subject triggered by needle trauma during a cell transplantation comprising administering to the subject an effective amount of an antibody (Ab) (optionally an antibody that binds a pro-inflammatory cytokine or a damage-associated molecular patterns (DAMPs) molecule;

• optionally an anti-TNF-α Ab (optionally Infliximab), an anti-IL-1β Ab (optionally Canakinumab), an anti-IFN-γ Ab (optionally Emapalumab), an anti-HMGB1 Ab, or an anti-IL-1α Ab) with a population of cells (optionally mDA cells).

A method of increasing cell survival in cell transplantation or increasing outgrowths of transplanted cells or reducing overgrowth during a cell transplantation, the method comprising co-transplanting an effective amount of a population of TREG cells with a second population of cells (“transplanted cells”;

• optionally mDA cells).

A method of increasing cell survival in cell transplantation or increasing outgrowths of transplanted cells or reducing overgrowth during a cell transplantation, the method comprising administering to the subject an effective amount of an antibody (Ab) (optionally, an antibody that binds a pro-inflammatory cytokine or a damage-associated molecular patterns (DAMPs) molecule;

• optionally, an anti-TNF-α Ab (optionally Infliximab), an anti-IL-1β Ab (optionally Canakinumab), an anti-IFN-γ Ab (optionally Emapalumab), an anti-HMGB1 Ab, or an anti-IL-1α Ab) and a population of cells (optionally mDA cells).